Lyell Immunopharma, INC 10-Q quarterly reports

Lyell Immunopharma's Q2 2026 report shows continued net losses and operating expenses, though progress is noted in its CAR T-cell therapy development for LBCL and mCRC.

Lyell Immunopharma reported progress in its CAR T-cell therapy pipeline, with ongoing clinical trials for ronde-cel and LYL273, alongside a wider net loss for the first quarter of 2026.

Lyell Immunopharma reported a reduced net loss in Q3 2025, driven by lower operating expenses, while advancing its lead CAR T-cell candidates ronde-cel and LYL273 into pivotal trials and further development.

Lyell Immunopharma reported a reduced net loss in Q2 2025, highlighted positive early clinical data for LYL314 in lymphoma, and secured $50 million in new financing.

Lyell Immunopharma announces its Q1 2025 financial results and provides an update on the clinical development of LYL314, its lead CAR T-cell therapy candidate.

Lyell Immunopharma's Q3 2024 report details ongoing clinical trials, a recent acquisition, and a strategic pipeline prioritization.

Lyell Immunopharma's Q2 2024 report details ongoing clinical trials, financial results, and strategic updates, including progress in their cell therapy programs.

Lyell Immunopharma, a clinical-stage cell therapy company, reported a net loss of $60.7 million for the first quarter of 2024, while advancing its pipeline of product candidates.